Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 4, 2012

Altravax Awarded $3.45M from NIAID for HIV-1 Vaccine Research

  • Altravax won two research grants totaling $3.45 million from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) toward research on antibody-inducing vaccines for HIV-1.

    Altravax says it will create vaccines designed to protect broadly against various strains of HIV-1, using its MolecularBreeding™ directed evolution technology licensed from Maxygen. MolecularBreeding consists of an in vitro homologous DNA recombination process or “DNA Shuffling” to create libraries of chimeric genes expressing variant proteins, plus screening technologies that include assays to rapidly identify immunogens best suited for a specific vaccine.

    “Our proposal to create vaccines that can more effectively stimulate the immune system represents a novel approach, and the recent award of these two grants will allow us to thoroughly explore this possibility,” says Robert Whalen, D.Sc., chief scientific officer at Altravax. “The current lack of viable vaccine candidates limits the ability of biotechnology companies to invest in HIV vaccine research with their own funds.”

    PLoS ONE will soon publish Altravax’ latest research on vaccines for HIV/AIDS, performed by Kristin Narayan, Ph.D., and colleagues from the company in collaboration with The Scripps Research Institute.

    In 2010, NIAID awarded Altravax two Small Business Innovation Research grants totaling $1.2 million for earlier HIV-1 antibody-inducing vaccine research using MolecularBreeding.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.